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ABSTRACT
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer and often
is not detected until late stages when cancer cells transcoelomically metastasize to
the abdomen and typically become resistant to therapy resulting in very low survival
rates. We utilize an orthotopic, syngeneic mouse model to study late stage disease
and have discovered that the tumor cells within the abdominal ascites are irreversibly
re-programmed, with an increased tumorigenicity and resistance to apoptosis.
The goal of this study was to characterize the reprogramming that occurred in the
aggressive ascites-derived cells (28-2 cells) compared to the original cell line used for
tumor induction (ID8 cells). Microarray experiments showed that the majority of genes
upregulated in the 28-2 cells belonged to the mevalonate pathway, which is involved
in cholesterol biosynthesis, protein prenylation, and activation of small GTPases.
Upregulation of mevalonate appeared to be associated with the acquisition of a p53
mutation in the ascites-derived cells. Treatment with simvastatin to inhibit HMG CoA
reductase, the rate limiting enzyme of this pathway, induced apoptosis in the 28-2 cell
line. Rescue experiments revealed that mevalonate, but not cholesterol, could inhibit
the simvastatin-mediated effects. In vivo, daily intraperitoneal simvastatin treatment
significantly regressed advanced stage disease and induced death of metastatic tumor
cells. These data suggest that ovarian cancer cells become reprogrammed, with
genetic mutations, and upregulation of the mevalonate pathway, which facilitates
the development of advanced stage disease. The use of statins to inhibit HMGCR may
provide novel therapeutic opportunities for the treatment of advanced stage EOC.

INTRODUCTION

model of EOC, we have shown that following interaction
with the ovarian microenvironment, transformed ovarian
epithelial cells derived from ascites (28-2 cells) become
irreversibly reprogrammed, with increased proliferative
capacity and resistance to apoptosis compared to the
original ID8 cell line used for tumor induction [3].
While the source of this reprogramming is still under
investigation, interaction with the hormone- and growth
factor-rich ovarian microenvironment is implicated.

Epithelial ovarian cancer (EOC) is the most lethal
gynaecologic malignancy and is the fifth leading cause of
cancer-related deaths in women [1]. A contributor to the
poor prognosis is the late stage of diagnosis, when tumor
cells have metastasized to the abdomen and have become
more aggressive and resistant to treatment [2]. Using
an orthotopic, syngeneic and immunocompetent mouse
www.impactjournals.com/oncotarget
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that TP53 mutations have been shown to interact with
the transcription factors SREBP-2 and nuclear factor Y
(NF-Y) [13, 20–23] and the specific R273H oncomorphic
mutation associates with SREBP transcription factors
to induce upregulation of mevalonate genes [13]. These
transcription factors potently induce expression of
HMGCR, which catalyzes the formation of mevalonate
pathway products [24–26]. Activation of the mevalonate
pathway by SREBP-2 has been shown to alter cellular
localization and activate YAP and TAZ, which are
mediators of the Hippo pathway and are potent oncogenes
[27, 28]. Similarly, NF-Y is known to increase expression
of the Rho family of small GTPases [29]. Through its
interaction with SREBP-2, mutated p53 can influence
expression of mevalonate genes [13] and the effects of
mutant p53 in breast cancer are mediated through the
mevalonate pathway [13].
In ovarian cancer, statins have been shown to induce
ovarian cancer cell death and enhance the cytotoxic effects
of chemotherapy drugs [30]. In vitro combination therapy
with cisplatin and fluvastatin synergistically disrupted
Ras signalling, resulting in decreased proliferation, and
increased apoptosis and cell cycle arrest in EOC cells [31].
Similarly, lovastatin has demonstrated synergistic anticancer actions with the chemotherapy drug doxorubicin
and can antagonize drug resistance in a host of ovarian
cancer cell lines [32]. Although limited data exist on the
effect of statins on ovarian cancer progression in vivo,
the in vitro preclinical data suggest that inhibition of the
mevalonate pathway may have important therapeutic
potential whether this approach is used alone or in
combination with traditional cytotoxic chemotherapy.
We hypothesized that inhibition of the mevalonate
pathway would reduce tumor cell viability in vitro and
inhibit tumorigenicity and metastatic potential in an
in vivo mouse model of advanced stage EOC.

Recent studies have highlighted the importance of the
hormonal environment of the ovary, and follicular fluid in
particular, that can induce DNA damage and mutations [4].
The mevalonate pathway facilitates multiple
metabolic functions. The products of the mevalonate
pathway include sterol isoprenoids such as cholesterol,
and non-sterol isoprenoids such as dolichol, heme-A,
isopentenyl, and ubiquinone [5, 6]. In the first committed
step of the mevalonate pathway, hydroxymethyl-glutaryl
coenzyme A (HMG-CoA) reductase (HMGCR) converts
HMG-CoA to mevalonic acid (Figure 1). HMGCR is
the rate-limiting enzyme of the mevalonate pathway [6].
Mevalonate can be reduced to isopentenyl pyrophosphate
(IPP) and dimethylallyl pyrophosphate (DMAPP).
DMAPP is then condensed by farnesyl pyrophosphate
(FPP) synthase to form FPP, which is the precursor of
cholesterol, steroid, and dolichol biosynthesis. DMAPP
can also be condensed by geranylgeranyl pyrophosphate
(GGPP) synthase to form GGPP. FPP and GGPP facilitate
protein prenylation, which mediates membrane attachment
and protein-protein interactions. FPP and GGPP are
involved in the prenylation, membrane localization, and
activation of small GTPases from the Ras, Rho, Rab and
Rac families that regulate a number of important cellular
functions and many are well established oncogenes. The
Ras-superfamily of proteins is associated with aggressive
ovarian cancer cell behaviour and progression of disease
(Reviewed in [7]).
Statins, originally designed as lipid-lowering drugs
to control hypercholesterolemia, inhibit HMG-CoA
reductase activity. This inhibition prevents the formation
of cholesterol, but also blocks protein prenylation due
to downstream depletion of FPP and GGPP [8]. This
upstream inhibition of the mevalonate and cholesterol
biosynthetic pathways is important from an anti-cancer
perspective [8] and our results suggest that statins may be
relevant anti-cancer agents in patients with reprogrammed
ascites cancer cells. In a number of cancer cell lines,
statins induce apoptosis in a HMG-CoA reductase-specific
manner [9], which has intensified interest in the anticancer
potential of these drugs.
Epidemiologic data suggests that people on statin
therapy may have a reduction in the risk of certain types
of cancers, by as much as 50% [10, 11]. In addition to
the protective effects of statins, they may also aid cancer
treatment by re-sensitizing chemoresistant cancer cells
[12]. A proposed mechanism for this re-sensitization is
a reduction in the heightened activity of the mevalonate
pathway that occurs in cells with TP53 mutations
[13], found in more than half of human cancers [14],
and almost universally in high-grade serous ovarian
cancer [15]. Combined statin treatment with cytotoxic
chemotherapy has resulted in synergistic anti-cancer
effects in vitro [16–18]. Mutant p53 is known to interact
with other transcription factors and modulate expression
and function of their target genes[19]. It is noteworthy
www.impactjournals.com/oncotarget

RESULTS
Exposure to the ovarian microenvironment
upregulates the mevalonate pathway in murine
ovarian cancer cells
An orthotopic, syngeneic mouse model of epithelial
ovarian cancer (EOC) was used in which cells were injected
under the ovarian bursa which allows the tumor cells to
colonize, invade through the basement membrane and
gain exposure to the ovarian microenvironment. Previous
work in our lab has shown that following interaction
with the ovarian microenvironment, these cells have
accelerated tumor growth and increased morbidity (3).
Our work shows that cell lines established after exposure
to the ovarian microenvironment (28-2 cells) demonstrate
an accelerated mitotic index, increased protein expression
of angiogenic, survival and proliferative proteins,
augmented migratory capacity and form tumors more
2
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28-2 cell population compared to the other populations.
We also queried the array for expression of SREBP-2,
which transcriptionally activates the mevalonate pathway
and found that 28-2 cells show a 2.4-fold increase in
expression compared to ID8 cells or cells collected
following intraperitoneal injection (Figure 1E).

rapidly than cells exposed directly to the peritoneal
microenvironment via intraperitoneal (IP) injection
(IP cells) [33]. Unsupervised clustering of the filtered set
of 33235 probes revealed that each individual line had
a distinct molecular profile. To identify genes that may
be responsible for the increased tumorigenicity observed
in cells exposed to the ovarian microenvironment, we
profiled 28-2, IP and ID8 cell lines on Agilent Whole
Mouse Genome arrays. Analysis of gene expression by
ANOVA (p < 0.05) with a Tukey’s post hoc test identified
the following differentially expressed probes: 2,756 probes
significantly different between 28-2 and ID8 lines; 4193
probes significantly different between the ID8 and lines
derived after IP injection; and 3191 probes significantly
different between the 28-2 and IP-injection (Figure 1).
A 28-2 specific gene list was generated by analyzing
the overlapping set of probes common between the two
28-2 comparisons (28-2 vs IP; 28-2 vs ID8), yielding 435
probes which are specific to cells reprogrammed after
exposure to the ovarian microenvironment. Two-way
hierarchical clustering illustrates a unique separation of
transcripts and their abundance between the 28-2 cells
and the other cell lines (Figure 1B). Gene ontological
analysis of the 28-2 cell gene expression signature
revealed significant enrichment in a number of categories
belonging to the ‘cholesterol biosynthetic process’,
‘cholesterol metabolic process’, ‘steroid biosynthetic
process’ and ‘lipid metabolic process’ (p < 0.001) gene
ontologies, amongst other biological processes (Table 1).
To explore this further, we looked specifically at the
cholesterol biosynthetic pathway (Figure 1C), which
converts the two-carbon metabolite acetyl-CoA into
the 27-carbon cholesterol molecule through a series of
enzymatic steps. Members of the cholesterol biosynthetic
pathway up-regulated in the 28-2 gene signature are
indicated by a red box in Figure 1C. The rate-limiting
step of the pathway occurs upstream with the conversion
of 3-hydroxy-3-methyl-glutarylCoA into mevalonate
by 3β-hydroxy3-methylglutharyl coenzyme A reductase
(HMGCR). Downstream of HMGCR is the mevalonate
pathway comprised of lipids that are synthesized from
the 5-carbon precursors, isopentenyl-pyrophosphates,
into the 15-carbon farnesyl pyrophosphate (FPP) and the
20-carbon geranylgeranyl pyrophosphates (GGPP). Both
FPP and GGPP are enzymatically fused to the C-terminus
of proteins through a process called prenylation, which
provides a lipid attachment for small GTPases such as Ras,
Rac, Rho and CDC42. Fusion of two FPP metabolites by
squalene synthase is the first committed step to cholesterol
synthesis and is mediated by squalene synthase. Further
modifications of squalene form cholesterol, which
functions in maintaining plasma membrane fluidity and
is a precursor for steroid hormone synthesis. As shown
in Figure 1, genes involved in all aspects of cholesterol
biosynthesis, farnesylation, geranylation, and protein
prenylation are expressed significantly higher in the
www.impactjournals.com/oncotarget

Inhibition of HMGCR by simvastatin induces
apoptosis in vitro
To interrogate the functional relevance of the
cholesterol biosynthetic pathway upregulation in our
model, we treated the original ID8 cells and two ascitesderived cell lines, 28-2 and 30-2,with simvastatin to
inhibit the rate-limiting step of cholesterol and mevalonate
synthesis and measure specific in vitro effects. We
observed a dose-dependent decrease in cell viability
after 96-hour simvastatin administration with an IC50
of 11.5 μM in the native ID8 cells, 3.9 μM in 28-2 cells
and 5.8 μM in 30-2 cells. We extended our findings
to include a variety of human cell lines including EOC
cell lines (SKOV3 and OVCAR3) and normal ovarian
surface epithelial cells (NOSE). Simvastatin decreased
viability in all cell lines tested and the IC50 values were
determined (Table 2). To confirm the decrease in viability
was due to cell death, ID8 and 28-2 cells were grown
on coverslips and apoptosis was quantified using the
TUNEL assay after simvastatin treatment (Figure 2).
TUNEL positive, pyknotic nuclei were first observed in
the 10 μM simvastatin group and high rates of apoptosis
were recorded in the 50 μM simvastatin treatment groups
in accordance with our viability data. At the 10 μM
simvastatin dose, 28-2 and 30-2 cells showed a significant
(p < 0.001) increase in apoptosis compared to untreated
controls, whereas at the 50 μM dose all three cell lines
(ID8, 28-2 and 30-2) had significantly higher (p < 0.001)
apoptotic cell death (Figure 2).

Mevalonate, not cholesterol, mediates
simvastatin-induced cell death
In order to specifically identify the role of the
cholesterol and mevalonate biosynthetic pathways in
maintenance of viability in the mouse EOC lines, we
treated cell lines with simvastatin and performed rescue
experiments by adding back mevalonate and cholesterol
(Figure 3). Administration of 500 μM mevalonate rescued
all cell lines tested (ID8, 28-2, 30-2, SKOV3, OVCAR3
and NOSE) whereas cholesterol could not rescue at any
of the doses tested (0.01, 0.1, 1.0, 10, 100 μM – data not
shown). Treatment of MOSEC with 0.01 μM – 50 μM
squalene could not rescue cells from simvastatin induced
cell death (data not shown); thus, we concluded that
metabolites downstream of mevalonate and upstream
of squalene are critical for survival of these cells after
HMGCR inhibition.
3
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Figure 1: The cholesterol biosynthetic pathway characterizes an ovarian microenvironmental gene signature (28-2).

(A) Venn diagram illustrating the differential gene expression profiling of mRNA isolated from cells exposed to the ovarian microenvironment
(intrabursal - 28-2) or control cells not exposed to the ovarian microenvironment (peritoneum -IP) compared to mouse naive ID8 cells.
(B) Two-way unsupervised hierarchical clustering of 28-2 specific gene signature indicated in (A), upregulated genes indicated in red
and downregulated genes in green. (C) Gene ontological analysis of the 28-2 gene signature revealed overrepresentation of cholesterol
biosynthetic pathway genes. The cholesterol biosynthetic pathway contains an upstream mevalonate pathway which synthesis isoprenoids,
dolichol and ubiquinone. Genes upregulated are indicated in red. (D) Relative expression of the rate-limiting enzyme, HMGCR, by
quantitative PCR. A significant increase in HMGCR in 28-2 cells validated our expression data n = 3 replicates; *p < 0.05. (E) Micorarray
data showed a 2.4-fold increase in expression of the transcription factor SREBP-2 in 28-2 cells, compared to parental cells used for tumor
induction (ID8 cells). There was also an increase in SREBP2 in 28-2 cells compared to cells injected directly into the peritoneum that did
not interact with the ovarian microenvironment (IP).
www.impactjournals.com/oncotarget
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Table 1: Increased expression of genes in the 28-2 gene signature
GO ACCESSION

corrected p-value Count in Selection

GO Term

GO:0009058
GO:0003824
GO:0044255
GO:0044237
GO:0006695
GO:0008203
GO:0005622
GO:0043231
GO:0043229
GO:0044424
GO:0009240

biosynthetic process
catalytic activity
cellular lipid metabolic process
cellular metabolic process
cholesterol biosynthetic process
cholesterol metabolic process
intracellular
intracellular membrane-bounded organelle
intracellular organelle
intracellular part
isopentenyl diphosphate biosynthetic process
isopentenyl diphosphate biosynthetic process,
GO:0019287
mevalonate pathway
GO:0046490
isopentenyl diphosphate metabolic process
GO:0008299|GO:0009241 isoprenoid biosynthetic process
GO:0008610
lipid biosynthetic process
GO:0006629
lipid metabolic process
GO:0030324
lung development
GO:0043227
membrane-bounded organelle
GO:0008152
metabolic process
GO:0043226
organelle
GO:0008654
phospholipid biosynthetic process
GO:0030838
positive regulation of actin filament polymerization
GO:0044238
primary metabolic process
GO:0060541
respiratory system development
GO:0030323
respiratory tube development
GO:0006694
steroid biosynthetic process
GO:0016126
sterol biosynthetic process
GO:0016125
sterol metabolic process
GO:0016740
transferase activity

0.0934628
0.002051266
0.0934628
0.048637476
7.618883E-9
5.409889E-4
0.001581868
0.001581868
0.001243249
0.001805784
0.008654

80
130
21
143
11
11
227
177
196
222
3

0.008654

3

0.008654
0.00287574
0.001243249
0.086196415
0.010353317
0.001581868
5.409889E-4
0.001189004
0.009288681
0.09294873
0.085513584
0.024802865
0.011691348
5.409889E-4
6.5381165E-8
0.00117981
0.057958957

3
6
19
27
11
177
188
197
10
4
143
11
11
11
11
11
52

Table 2: Simvastatin IC50 values determined from WST1 assay
Cell Line

IC50

ID8
28-2
30-2
SKOV3
OVCAR3
NOSE
iOvCa130 p53 WT
iOvCa147 p53 MUT

11.5 μM
3.9 μM
5.8 μM
13.8 μM
7.2 μM
3.7 μM
10.2 μM
2.9 μM

Geranylgeranyl pyrophosphate rescues MOSEC
from simvastatin-induced apoptosis

activity by directing proper subcellular localization to
the plasma membrane, we hypothesized that inhibition
of HMGCR by simvastatin may deplete the cellular
pool of FPP or GGPP and prevent proper prenylation
of small GTPases, reducing their activity, leading to
apoptosis. Following co-treatment of MOSEC cells with
20 μM simvastatin and 5 μM GGPP, GGPP reversed the

The mevalonate pathway functions to generate
various 5-carbon isopentyl-pyrophosphates building
blocks to form isoprenoids, including FPP, GPP and GGPP.
As isoprenoids are critical determinants of small GTPase
www.impactjournals.com/oncotarget
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Figure 2: Inhibition of HMG-CoA induces apoptosis of MOSEC in vitro. (A) Simvastatin treatment of ID8 and 28-2 cells induce

apoptotic cell death measured by the TUNEL assay in a dose-dependent manner. TUNEL positive cells (yellow) exhibit characteristic
pyknotic morphology characterizing apoptotic cells. Cells were fixed on coverslips 24 hrs after simvastatin treatment. (B) Analysis of
percentage of TUNEL positive cells reveals a significant (*p < 0.001) increase in higher doses of simvastatin when compared to controls
(SF). N = 3, one-way ANOVA, Dunette’s poc hoc test. SF - serum free control, VEH - simvastatin vehicle control, 0.1 μM – 0.1 μM dose
of simvastatin, TUNEL - terminal deoxynucleotidyl transferase dUTP nick end labeling.

Figure 3: Mevalonic acid, but not cholesterol can rescue EOC cell lines from simvastatin induced cell death. Treatment

of 500 μM mevalonic acid (MEV) rescues various mouse (ID8, 28-2, 30-2) and human (SKOV3, OVCAR3) cell lines from 20 μM
simvastatin cell death determined by viability assay. Administration of water-soluble cholesterol (CHOL) did not rescue all cell lines tested
from simvastatin induced cell death. SF - serum free, NOSE - normal ovarian surface epithelial cells, SIM VEH - simvastatin vehicle
control, MEV VEH - mevalonic acid vehicle control, SQUAL - squalene.

www.impactjournals.com/oncotarget
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6, 15 and 19. Centric fusions were not observed, however
all metaphases contained two reciprocal translocations
der(4)T(4;8) and der(15)T(10;15). The derivative
Chr 8 and Chr 10 counterparts were only observed in
1 metaphase. These results partially confirm the G-banded
karyotype described by Roby et al. [34], specifically the
presence of trisomies and tetrasomies, although with some
differences. We could not detect the T(15;18) suggested
by Roby et al. [34], but identified two other reciprocal
translocations. The 28-2 karyotype is clearly derived from
the ID8 genome, showing very similar chromosomal
abnormalities with some differences: less copies of Chr
6, 8, 10, X, but tetrasomy of Chr 4, 11 and 6-8 copies
of Chr 15 including mostly two copies of the der(15)
T(10;15) translocation. The other translocation from
ID8 der(4)T(4;8) was also present in every metaphase.
Three unique reciprocal translocations were identified
in 28-2, including T(4;X), T(5;17) and T(11;X). Both
derivative counterparts of these rearrangements were
observed, although der(5)T(5;17) was mostly present
as del(5). Frequent deletion of one copy of Chr 1 and
12 is also specific to 28-2. Centromere amplification or
dicentric chromosomes were also observed in both cell
lines, but much more frequently in 28-2 as compared
to ID8 (41% vs 20%, respectively). Flow cytometric
comparison of G1 peaks of the cell cycle confirmed
the highly amplified genomes in both ID8 and 28-2,
as compared to the normal fibroblast control (327, 308, 190,
respectively), but also showed a slight reduction (6.2%) of
genome size in 28-2 compared to ID8 (Figure 7E).
iOvCa147 and 28-2 cells exhibited increased
expression of SREBP-2 and the small GTPase RhoA
(Figure 8). Simvastatin treatment did not alter expression
of SREBP-2, but did result in a decrease in expression
of RhoA in 28-2 and iOvCa147 cells, but not iOvCa130
or ID8 cells (Figure 8). Immunofluorescence was also
performed for the members of the HIPPO pathway YAP
and TAZ as this pathway has been implicated in cancer
onset and progression and YAP and TAZ are activated by
small GTPases such as RHO [28]. 28-2 and iOvCa147 cells
had increased staining for these factors, with prominent
nuclear localization, compared to ID8 or iOvCa130 cells
(Figure 9). Simvastatin treatment reduced expression
of YAP and TAZ and induced a shift to cytoplasmic
localization in 28-2 and iOvCa147 cells (Figure 9). Cell
fractionation experiments confirmed a shift from nuclear
to cytoplasmic localization of Yap and Taz following
simvastatin treatment, particularly in the p53 mutant 28-2
and iOvCa147 cells (Figure 9). Human ascites derived
ovarian cancer cells known to be wild-type for TP53
(iOvCa130) and TP53 mutant (iOvCa147) were treated
with increasing doses of simvastatin for 24 h and subjected
to WST-1 assay to quantify cell viability.
iOvCa147
cells had enhanced sensitivity to simvastatin, compared to
iOvCa130 cells, with a significant (p < 0.05) reduction in
viability at all doses beyond 0.5 μM (Figure 10).

simvastatin-induced apoptotic cell death in MOSEC cells
(Figure 4). Co-treatment with 50 μM FPP did not elicit the
same rescue effect and a significant decrease in viability
was observed (Figure 4).

Simvastatin inhibits tumor growth in the
syngeneic model and reduces cell migration
in vitro
To investigate the in vivo effects of HMG inhibition
in EOC, we applied our syngeneic, orthotopic mouse
model of EOC in which spontaneously-transformed
murine ovarian surface epithelial ID8 cells were injected
into the bursa of recipient mice. Following tumor
induction, mice received daily intraperitoneal injections of
simvastatin (1 mg/kg/day) or PBS. Mice were sacrificed
on day-60 and tissues were measured and collected.
Mice that received daily IP injections of simvastatin
demonstrated a significant reduction in tumor size and
weight when compared to tumors collected from the PBS
injected control group (Figure 5; p < 0.05). Murine EOC
cells were also treated with sublethal doses of simvastatin
for 48hrs, and a scratch assay was performed to identify
the effects on cell migration. The migration of 28-2 cells
was inhibited to a greater extent than ID8 cells (Figure 5C–
5D). Simvastatin treatment was also able to reduce disease
morbidity in advanced-stage ovarian cancer.
When
treatment was initiated at 60 days post tumor induction
(PTI), there was significant (p < 0.05) tumor regression
(Figure 6A). There was also a reduction (p < 0.05)
in the viability of cells collected from ascites from
simvastatin treated mice (Figure 6B). and reduced number
of metastatic peritoneal tumors (Figure 6C).

Ascites-derived cells following orthotopic tumor
initiation are p53 mutant and have genomic
instability
We hypothesized that the more aggressive phenotype
of the 28-2 cells may be related to the presence of mutated
TP53, which is seen in the majority of high-grade serous
ovarian cancers in humans. Human ascites-derived cells
known to be TP53 wild-type (iOvCa130) and TP53 mutant
(iOvCa147) as well as murine ID8 and ascites-derived
28-2 cells were subjected to immunofluorescence and
Western blot analysis with antibodies specific for total p53
and mutant p53. iOvCa147 and 28-2 cells exhibited high
expression of total and mutant p53, compared to iOvCa130
and ID8 cells (Figure 7A–7B). Sequence analysis of 28-2
cell p53 cDNA detected a mutation in codon 273 (CGTCAC;Arg-His) of exon 8 (Figure 7C).
Chromosomal analysis revealed significant
genomic instability with severe numerical and structural
abnormalities in both ID8 and 28-2 cell lines (Figure 7D).
The ID8 genome is more than trisomic, being mostly
tetrasomy for Chr 1, 2, 5, 8, 10, 17 and five copies of Chr
www.impactjournals.com/oncotarget
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Ascites-derived cells have increased H3
acetylation at the HMGCR NF-Y binding site

to immunohistochemistry or Western blot analysis for
HMGCR and the small downstream GTPases Rac1 and
RhoA. Following IHC, software analysis was used to
quantify the percentage of immunopositive tissue in
both the primary ovarian tumors as well as the metastatic
peritoneal tumors. There was increased expression of
HMGCR and both GTPases in the metastatic peritoneal
tumor tissue, compared to the primary tumors. Although
the metastatic tumors were smaller, they had increased
levels of all three proteins (Figure 12A–12B).

It is well established that increases in the acetylation
of histone H3 at K9 and K14 is associated with chromatin
activation and increased RNA polymerase II recruitment
[35, 36]. Therefore to investigate if transformation of these
cells led to augmented HMGR transcription as a result
of increased histone H3 [K9,14] acetylation, chromatin
immunoprecipitation (ChIP) was employed in ID8 and
28-2 cells. ChIP revealed increased acetylation of Histone
H3 [K9/K14] within the NF-Y site (−68 to −64) of the
HMGCR promoter in 28-2 cells, compared to ID8 cells
(Figure 11), suggesting epigenetic activation of HMGCR.
The non-specific binding of IgG was tested and found to
be minimal (Ct value > 34, data not shown).

DISCUSSION
We have demonstrated that MOSEC lines exposed
to the ovarian microenvironment increase expression of
various enzymes of the mevalonate pathway. Our data
also show that isoprenoid generation is critical for the
viability of these cell lines and that simvastatin can inhibit
the growth of ovarian lesions in our immunocompetent
mouse model of EOC. We have previously characterized
the effects of injecting ID8 cells orthotopically into
the ovarian bursa of recipient mice and compared the
effects to mice that receive ID8 cells injected directly

Metastatic peritoneal tumors have greater
expression of members of the mevalonate
pathway compared to primary tumors
At 90d PTI, primary tumors and metastatic
peritoneal tumors were collected, fixed, and subjected

Figure 4: Geranylgeranyl pyrophosphate (GGPP), but not farnesyl pyrophosphate (FPP) rescues mouse ovarian
cancer cell lines from statin induced cell death. (A) Transformed MOSEC lines co-treated with simvastatin and GGPP, prevented

simvastatin induced cell death measured by WST-1 viability assay. Interestingly, coadministration of FPP did not rescue MOSECs cells after
HMGCoA inhibition by simvastatin. Viability was measured by WST1 assay. *p < 0.05 (B) TUNEL analysis of simvastatin, mevalonic
acid, GGPP and FPP treated MOSEC lines confirm that the downstream metabolites, mevalonic acid and GGPP, can rescue MOSEC
lines from simvastatin induced apoptosis. FPP was unable to rescue simvastatin induced cell death. SF - serum free control, SIM VEH simvastatin vehicle control, SIM - simvastatin, MEV VEH - mevalonic acid vehicle, FPP VEH - farnesyl pyrophosphate vehicle control,
GGPP - geranylgeranyl pyrophosphate.
www.impactjournals.com/oncotarget
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into the peritoneal cavity and discovered a striking
reprogramming and aggressiveness following interaction
with the ovarian microenvironment [3]. Data from the
current study demonstrate that exposure to the ovarian
microenvironment significantly increases expression of
members of the mevalonate pathway.
To assess the effect on cell viability, we utilized
statins to inhibit the mevalonate pathway. Statins are
potent inhibitors of HMG-CoA reductase, which catalyze
formation of mevalonate from HMG-CoA and is the
rate-limiting step in the mevalonate and cholesterol
biosynthetic pathways [6]. In vitro treatment of MOSEC
lines with simvastatin revealed it induced apoptosis in a
dose-dependent manner. Interestingly, the ID8 parental
cell line was less sensitive to simvastatin-induced
apoptosis when compared to the 28-2 and 30-2 cell lines,
which were derived from ascites following interaction with
the ovarian microenvironment. Concurrent treatment of

MOSEC lines with simvastatin and mevalonate prevented
simvastatin-induced apoptosis whereas squalene and
cholesterol could not rescue MOSEC lines. We concluded
that a metabolite generated in mevalonate pathway,
which is upstream of squalene and cholesterol, must be
essential for the viability of MOSEC lines. Studies have
shown that statins can induce apoptosis through activation
of the p38 [37], caspase-3 [38], DR5/CHOP/pJNK [39],
Bax [40], TRAIL [41] and suppression of Akt [38, 42],
Bcl-2 [40, 43], mTOR [42]. Studies in C. elegans,
suggest depleting the cells of isoprenoid units initiates the
endoplasmic reticulum unfolded protein response (UPRer)
followed by growth arrest and apoptosis [44–46]. Current
investigations in our laboratory are underway to identify
the pathway(s) that mediate simvastatin induced apoptosis.
The mevalonate pathway includes the formation
of various isopentenyl pyrophosphate base molecules
including
farnesyl-pyrophosphate
(FPP)
and

Figure 5: Simvastatin treatment reduces scratch wound healing in vitro and tumor weight in vivo. (A–B) 1.0 × 106 ID8

cells were placed in the ovarian bursa and permitted to recover for a week before receiving 1 mg/kg/day simvastatin IP for 60 days. At
necropsy, SIM treated mice had smaller tumors with decreased weight *p < 0.05. (C) Representative photomicrographs of simvastatin
treated ID8 and 28-2 cells at 0 and 48 hours timepoints after scratch wounding. (D) Quantification of the percent scratch wound closure
reveals a significant (*p < 0.05) decrease in closure at higher doses of simvastatin. PBS CONT - PBS injected control, SIM - 1 mg/kg/day
simvastatin treated group, IP - intraperitoneal.
www.impactjournals.com/oncotarget

9

Oncotarget

geranylgeranyl-pyrophosphate (GGPP) downstream
of mevalonate synthesis. Collectively FPP, GGPP and
other isopentenyl-pyrophosphate molecules (termed
“isoprenoids”) take part in post-translational modification
of proteins through a process termed prenylation [45–47].
Target proteins like the Ras superfamily of small GTPases
require prenylation for proper function by localizing
them to the plasma membrane in close proximity to
their substrates [48]. It has been predicted that over 300
proteins undergo prenylation including Ras, Rho, RAB and
ARF [49]. Due to the observation that statin-induced cell
death could be rescued by mevalonate, but not squalene or
cholesterol, we tested whether isoprenoids were required
to prevent statin-induced apoptosis. We identified GGPP
as the isoprenoid required to rescue MOSEC cells from
apoptotic cell death. Prenylation of target proteins with
GGPP, or geranylation, occurs with Rho, RAB and ARF,

implicating a loss of subcellular localization and thus
function leading to cell death in our model.
Our study also illustrated that daily treatment of
1 mg/kg simvastatin in vivo resulted in a significant
decrease in tumor progression at 60 days post tumor
induction. Retrospective analysis of statin use in ovarian
cancer [50, 51], endometrial cancer [51], gliomas [52],
colorectal cancer [53], hepatocellular cancer [54], and
prostate cancer [55] reveal reduced overall mortality,
suggesting that statin therapy may have a protective effect
against some cancers. Studies have shown that statins
can affect multiple stages of ovarian cancer progression
including: metastasis [56, 57], chemoresistance [58], and
cytotoxicity [31, 32, 59, 60]. Treating ovarian cancer cells
with statins and inhibitors of RhoA resulted in decreased
cell dissemination in a NUDE mouse model of ovarian
cancer [57]. It is noteworthy that co-treatment with

Figure 6: Simvastatin induces regression of advanced stage ovarian cancer. Tumors were orthotopically induced with
ID8 cells in syngeneic mice and allowed to grow until 60 d PTI at which time they received daily IP injections of PBS or simvastatin
(1 mg/kg/d) for 20 d. (A) Tumors from mice treated with simvastatin had regressed to a significantly (*p < 0.05) smaller size, compared
to PBS treated controls. (B) Simvastatin treated mice had a significant (*p < 0.05) reduction in percentage of viable ovarian cancer cells
collected from ascites. (C) Simvastatin treatment reduced the number of metastatic peritoneal tumors, compared to PBS treated controls.
www.impactjournals.com/oncotarget
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Figure 7: Reprogrammed EOC cells exhibit p53 mutations and genomic instability. (A) P53 MUT human EOC cells

(iOvCa147, validated to have p53 mutation in Exon 6 – sequencing performed by Dr. G. DiMattia) showed increased expression of p53
protein compared to p53WT cells (iOvCa130; verified p53 WT – sequencing performed by Dr. G. DiMattia) using immunofluorescence
with specific antibodies for each isoform. Similarly, reprogrammed murine ascites-derived EOC cells (28-2) had increased expression
of WT p53 and mutant p53 protein, compared to the non-reprogrammed parental murine ID8 EOC cells. (B) Cell lysates were subjected
to Western blot analysis for expression of total and mutant p53. 28-2 and iOVca147 cells demonstrated increased expression of total
and mutant p53 compared to ID8, IP, and iOvCa130 cells. (C) 28-2 cells have a CGT to CAT mutation in Exon 8 of the p53 gene.
(D) Spectral karyotyping showed extensive numerical and structural chromosome abnormalities in both ID8 and 28-2 cells. The presence
of three translocations and three deletions specific to 28-2 emphasizes the activity of structural rearrangements during its development and
adaptation. (E) The highly amplified genomes of 28-2 and ID8 cells were visualized by the G1 peaks of the cell cycle as measured by flow
cytometry and compared to a diploid fibroblast control. Numerical instability resulted in a ~6.2% smaller genome size of 28-2, as visible
from the difference between the G1 peaks of 28-2 vs. ID8 cells.
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lipophilic statins and cisplatin or doxorubicin results in
apoptosis through activation of the intrinsic and extrinsic
apoptotic pathways [31, 32, 58–60]. All of these reported
mechanisms may explain the anti-tumor effect of
simvastatin in our mouse model of EOC.
Interestingly, we have discovered that the ovarian
cancer cell reprogramming that occurs within the tumor
microenvironment may involve the acquisition of a p53
mutation. Our data, and data from others, demonstrate
that ID8 cells are p53 wildtype [61]. However, 28-2 tumor
cells within abdominal ascites showed increased p53
levels, which is an indication of p53 mutation affecting
protein stability [62]. These cells showed strong reactivity
to an antibody specific to mutant p53 and sequencing data
showed mutation in codon 273 of exon 8 within the DNA
binding domain of p53. This R273H mutation in 28-2 cells
is the most frequent TP53 mutation in high-grade serous
ovarian cancer and accounts for 8% of all TP53 mutations
[63]. This is classified as an oncomorphic, or gain-offunction, mutation associated with increased invasion,
survival, proliferation, angiogenesis, and resistance to

chemotherapy [64–66]. Interestingly, discordance between
the p53 status of primary tumor cells and ascites-derived
ovarian cancer cells has been reported in women where
primary tumor cells are p53 wild-type, while ascitesderived cells have acquired a p53 mutation [67]. The
factors involved in driving this mutation are currently
unknown. Some hypothesize that the growth-factorand hormone-rich environment within the ovary can
increase the aggressiveness of transformed ovarian cancer
cells, leading to upregulated metabolism, the formation
of reactive oxygen species, and the induction of DNA
damage [4]. Recent studies have implicated the fallopian
tube epithelium (FTE) as the origin of high-grade serous
adenocarcinoma. Mutations of TP53 are typically seen
early in the FTE and some have suggested that follicular
fluid released at ovulation can flow into the fallopian tube
and can induce DNA damage and p53 mutation [68].
P53 mutations in the ovarian surface epithelial cells have
also been implicated in the progression to Type II, highgrade ovarian carcinomas [69]. The spectral karyotype
confirmed the origin of 28-2 from ID8 cells, as a similar

Figure 8: p53MUT (28-2, murine; iOvCa147, human) have increased SREBP-2 and RhoA expression compared to
p53WT (ID8, murine; iOvCa130, human) EOC cells. Increased expression of the HMGCR transcription factor SREBP2 was seen

in p53MUT compared to p53WT cells (SREBP2 red, nuclei blue). Expression of the small GTPase RhoA, which is a downstream protein
in the mevalonate pathway was upregulated in the p53MUT ascites derived cells (RhoA green, nuclei red). Treatment with the mevalonate
pathway inhibitor simvastatin (20 μM) caused greater inhibition of RhoA expression in p53MUT metastatic ascites-derived cells (28-2,
iOvCa147) than primary tumor cells (ID8) or p53WT (iOvCa130) ascites derived cells.
www.impactjournals.com/oncotarget
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Figure 9: Simvastatin induces change in YAP and TAZ expression from nuclear to cytoplasmic localization in p53MUT
EOC cells. (A) P53MUT 28-2 (murine) and human (iOvCa147) ascites-derived EOC cells show strong nuclear localization of YAP (red)
and TAZ (green), while p53WT murine (ID8) and human (iOvCa130) EOC cells exhibit reduced or cytoplasmic staining. Treatment with
20 μM Simvastatin for 24 h resulted in reduced expression of YAP and TAZ and more cytoplasmic localization. Nuclei are counterstained
blue with DAPI stain. (B) Cells were lysed and separated into cytoplasmic and nuclear fractions and subjected to Western blot analysis of
Yap and Taz. Simvastatin treatment resulted in a shift in expression of YAP and Taz from nuclear to cytoplasmic localization and this shift
was more pronounced in 28-2 and iOvCa147 cells. ID8 and 28-2 lanes were run and imaged on the same gel but are shown separately as
some extraneous lanes were omitted.
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Figure 10: Simvastatin reduces viability of human ascites-derived EOC cells. P53WT (iOvCa130) and p53MUT (iOvCa147)
cells were cultured in the presence of Simvastatin (20 μM) for 24 hr and subjected to WST-1 assay to measure viability. EC50 values were
calculated for cell response to simvastatin for each cell type. Simvastatin had a more potent effect on viability in iOvCa147, compared to
iOvCa130 cells. *indicates statistical difference between cell lines for each treatment concentration (p < 0.05); n = 3 replicates.

Figure 11: Increased acetylation of histone H3 [K9,14] surrounding the NF-Y site in the promoter of HMGCR in
Re-programmed 28-2 Cells. ChIP analysis (n = 3 independent samples) demonstrated increased acetylation of the NF-Y site in the

promoter of HMGCR in the ascites-derived 28-2 cells compared to the parental ID8 cells used for tumor induction. *p < 0.05 by t-test.
www.impactjournals.com/oncotarget
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pattern of numerical and structural abnormalities were
detected as well as several 28-2 unique characteristics. The
ploidy level of several chromosomes was reduced, and a
few increased in 28-2 resulting in a 6.2% smaller genome
size by flow cytometry. The increased frequency of
abnormal centromeres in 28-2 could also contribute to the
prominent numerical instability that was described in other
highly amplified human ovarian tumor genomes [70].
However, the three unique reciprocal translocations
and three deletions emphasize the activity of structural
rearrangements during the development and adaptation
of 28-2. Interestingly, the hypothesized breakpoints in
T(4;8) and T(10;15) translocations might be connected to
frequently observed breakpoints in human ovarian tumors
[71], thus emphasize the potential functional role of these
chromosome segments. Tumor cell genomic instability has
been shown to be an important predictor of outcome in

patients with ovarian cancer [72], and this may account
for some of the aggressiveness seen in the metastatic cells
within ascites. Mutant p53 is known to interact with other
transcription factors and modulate expression and function
of their target genes[19]. For example, mutant p53 interacts
with the transcription factors SREBP-2 and nuclear factor
Y (NF-Y) [13, 20–23]; both SREBP-2 and NF-Y can
potently induce HMGCR expression, which catalyzes
activation of the mevalonate pathway [24–26]. Indeed,
we demonstrate via ChIP analysis that the reprogrammed
28-2 cells exhibited increased histone acetylation
[K9, 14] of the NF-Y site in the HMGCR promoter
region in the reprogrammed 28-2 cells (Figure 12),
suggesting epigenetic upregulation of HMGCR
transcription and ultimately activation of the mevalonate
pathway in these cells. Activation of the mevalonate
pathway by SREBP-2 has previously demonstrated to

Figure 12: Metastatic peritoneal tumors have increased expression of members of the mevalonate pathway. (A) Primary

and metastatic tumors from ID8 injected mice (n = 6/group) were collected and stained for HMGCR and small GTPases Rac1 and RhoA.
Metastatic secondary tumors had a significantly (*p < 0.05) higher percentage of tissue immunopositive for the enzyme and GTPases than
primary tumors. Scale bars are 20 μM (B) Western blot was performed on tumor lysates from primary and metastatic tumors. Metastatic
tumors had higher expression of HMGCR, Rac1 and RhoA, compared to primary tumors (*p < 0.05).
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regulate localization and activation of YAP and TAZ,
which are mediators of the Hippo pathway and are potent
oncogenes [27, 28]. Similarly, NF-Y is known to increase
expression of the Rho family of small GTPases [29].
Mutant p53 has been shown to increase synthesis of
mevalonate, which drives a more tumorigenic phenotype
in a 3D model of breast cancer [13]. Increased expression
of mevalonate and sterol biosynthesis enzymes in this
model was due to an association between mutant p53 and
SREBP transcription factors. Although only in two murine
and human cell lines, the ascites-derived cells with a p53
mutation demonstrate increased activity of the mevalonate
pathway, as well as an increased susceptibility to staininduced cell death, suggesting that in response to p53
mutation, there is an enhanced reliance on the mevalonate
pathway for viability.
With this enhanced reliance on the mevalonate
pathway, targeting this pathway with statins can
preferentially and potently induce death of tumor cells

within the abdomen. As the metastatic abdominal tumors
appear to have a similar upregulation of the mevalonate
pathway seen in the ascites-derived cells, we hypothesize
that the abdominal tumors may also be exquisitely sensitive
to statin inhibition. Our in vivo experiments of advanced
stage disease support this hypothesis, as indicators of
disease morbidity were dramatically reduced following
simvastatin treatment started in mice with advanced
stage ovarian cancer. This is a significant finding, as
the abdominal disease associated with advanced stage
ovarian cancer is most often responsible for the morbidity
and mortality associated with this disease. Our working
hypothesis is that mutant p53 induces NF-Y and SREBP-2
(and possibly others) to transcriptionally activate HMGCR,
resulting in upregulation of the mevalonate pathway,
enhanced GTPase activity, and stimulation of survival
pathways, such as the HIPPO pathway (Figure 13). Our
study also demonstrated significant genomic instability in
the re-programmed ascites derived 28-2 cells, which may

Figure 13: Working model of the reprogramming of metastatic ascites cells in ovarian cancer. Following interaction

with the ovarian tumor environment, circulating tumor cells acquire a p53 Mutation. Mutant p53 binds and activates transcription factors
such as NF-Y and SREBP2 which bind to the sterol regulatory element (SRE) in the HMGCR promoter. Along with specificity protein 1
(SP1), NF-Y and SREBP2 increase transcription of HMGCR, which upregulates the Mevalonate pathway. Increased Mevalonate stimulates
the formation of isopentenyl pyrophosphate (IPP). IPP can then lead to the formation of geranyl pyrophosphate (GPP) and farnesyl
pyrophosphate (FPP). FPP can lead to synthesis of cholesterol through squalene and can also lead to prenylation of RAS. Our data suggest
that cholesterol is not involved in the reprogramming of metastatic ascites cells. Geranylgeranyl pyrophosphate (GGPP) is responsible for
prenylation of the Rho family of small GTP-binding proteins and subsequent activation of Hippo pathway proteins YAP and TAZ. Statin
treatment blocks the enzyme HMG-CoA reductase (HMGCR) and its ability to produce mevalonate, effectively inhibit downstream process
of this pathway.
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RNA extraction and hybridization to genechip
arrays

have also contributed to the increased aggressiveness and
reduced apoptosis evident in these cells. Increased copy
number variations has been implicated in the development
of aggressive high grade serous EOC [73, 74], and may
lead to genetic influences in addition to the p53-mediated
changes seen in our cells.
In summary, this study illustrates that mouse tumor
cells exposed to the ovarian microenvironment acquire
gene mutation and experience genomic instability,
which is associated with increased mevalonate pathway
activity. Due to the reliance on the mevalonate pathway,
simvastatin is particularly cytotoxic to reprogrammed,
ascites-derived murine and human ovarian cancer cells.
Our in vivo data provide pre-clinical evidence to support
continued exploration of statin use in advanced stage
human EOC.

Total RNA was extracted from 1 × 107 MOSEC cells
grown on 100 mm culture dishes using RNeasy Minikits
(Qiagen). RNA was extracted from triplicate values of ID8,
28-2 and IP and OT cell lines, quantified using a UV-VIS
spectrometer (Nanodrop ND-1000) and RNA integrity was
confirmed using the Agilent 2100 Bioanalyzer RNA Nano
kit LabChip kit (Agilent Technologies). A total of 2 μg of
total RNA was labelled using Agilent’s Low RNA Input
Amplification kit for 2-colour design for hybridizing to the
Whole Mouse Genome Array (Agilent).

Statistical analysis of gene expression profiles
Quality control of expression data was confirmed
using the ARRAYQUALITY package in R and
Bioconductor [76]. Data was preprocessed and normalized
using Agilent’s spatial detrending normalization and
imported into GeneSpring for analysis. Data was log
(Base 2) transformed, median centered, and divided into
three groups: ID8, 28-2, and IP. Prior to analysis, the
data was filtered to remove the confounding effect probes
that show no signal may have on subsequent analysis
[77]. Only probes that were in the upper 20 to 100th
percentile of the distribution of intensities in 100% of
any of the 1 of 3 above categories were allowed to pass
through this filtering. A one-way ANOVA using a FDR
Benjamini and Hochberg multiple testing correction (q
< .05) [78] was performed, followed by a Tukey HSD
post-hoc test for differences between select groups.
Overlapping sets of significant probes were generated to
find line specific lists. For example, to generate a 28-2
specific gene list, shared probes between 28-2 vs ID8 and
28-2 vs IP were determined. These results were further
filtered with a minimum 2-fold difference cut-off. Gene
ontology analysis [79] was used to determine functionally
significant sets of co-regulated transcripts (q < 0.1 cut-off).
All clustering was done using two-way hierarchical
clustering with a Pearson centered distance metric and
average linkage rules.

MATERIALS AND METHODS
Reagents and cell lines
Simvastatin, geranylgeranyl pyrophosphate (GGPP),
farnesyl pyrophosphate (FPP), mevalonate (MEV),
squalene and water-soluble cholesterol were purchased
from Sigma. Simvastatin was prepared according to Sadghi
et al., 2000 to activate the drug into its proform [75].
GGPP, FPP, MEV, squalene and water-soluble cholesterol
were prepared according to manufacturer’s instructions.
Culture medium, glutamine and fetal bovine serum
(FBS) were purchased from Life Technologies. The
following spontaneously transformed mouse ovarian
surface epithelial cells (MOSEC) lines were cultured with
DMEMwith 10% FBS: ID8, 28-2, 30-2, IP and OT. The
28-2, 30-2, IP and OT lines were derived from ID8 cells
that were obtained from mice after grafting ID8 cells into
various microenvironments: 28-2 and 30-2 were isolated
from the ascites of intrabursal injected cells and had thus
interacted with the ovarian microenvironment. IP cells
were obtained from the ascites of following intraperitoneal
injection and had interacted with the peritoneal, but not
the ovarian environment. The OT line was obtained from
explant culture of ovarian tumors from an intrabursal
injection, and thus had interaction with the ovarian
microenvironment, but had not circulated within the
peritoneum [33]. Human EOC lines, OVCAR(ATCC) and
SKOV3 (ATCC) were cultured in RPMI with 20% FBS and
McCoy’s 3A media with 10% FBS respectively. Primary
human EOC cells (iOvCa130 and iOvCa147 cell lines)
were cell lines derived from the ascites of patients with
Stage IIIC high-grade serous ovarian cancer patients and
cultured in DMEM with 10% FBS and 1% antibiotic/
antimycotic (Gibco). All human cell lines were collected
and handled in accordance with ethics approval and patient
consent guidelines at Western University (HSREB 12668E).
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WST1 viability assay
To determine the effects of simvastatin treatment
on cell lines tested, cells were plated in 96-well plates,
incubated for 48 hrs before serum deprivation and treated
24 hrs later with various doses (0.01, 0.05, 0.1, 0.5, 1.0,
5.0, 10, 20, 50 and 100 μM ) of simvastatin. A second
treatment was performed 48 hrs post-initial treatment
and cells were incubated with the tetrazolium salt,
WST1, according to manufacturer’s instructions (Roche).
After incubation at 37°C for 2 hrs, plates were read on
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spectrometer at 450 nm with a reference wavelength of
630 nm on an EL800 Universal microplate reader (Biotek
Instruments, Inc). For rescue experiments, cells were coincubated with 20 μM simvastatin and either 500 μM
mevalonate, 10 μM squalene, 1 μM cholesterol, 5 μM
GGPP or 50 μM FPP at the zero time point and 48-hr time
point followed by data collected by WST1 as described
above.

reaction mixture, counterstained with DAPI and mounted
with prolong gold (Life Tech). Photomicrographs were
collected using an Olympus BX61 fluorescent microscope
at 200× magnification and percent TUNEL-positive
cells were determined using metamorph version 7.6.0.0
(Molecular Devices) from 5 fields of view. All TUNEL
experiments were repeated in triplicate. Add-back
experiments were conducted in a similar fashion except
cells were co-treated with 20 μM simvastatin and 500 μM
mevalonate, 5 μM GGPP or 50 μM FPP.

Immunofluorescence
Immunofluorescence was performed on in vitro
cultured ovarian cancer cells to determine expression
of p53 and mutant p53, and changes in localization of
SREBP-2, RhoA, YAP, and TAZ following simvastatin
treatment. Briefly, for determination of p53 status, ascitesderived human ovarian cancer cells were cultured on glass
coverslips in DMEM containing 10% FBS until 60–80%
confluent. Cells were then fixed with 10% neutral-buffered
formalin and permeabilized in 1% Triton X-100. Cells
were incubated with anti-total p53 (Abcam ab26; 1:600
dilution) or anti-mutant p53 (Abcam ab32049; 1:500
dilution) overnight at 4°C. Cells were then incubated
with secondary antibody (anti-rabbit 1:100 dilution) for
2 hours at RT, washed and counterstained with DAPI
before mounting on glass slides with Prolong Gold
antifade (Cell Signaling). Expression of SREBP-2, RhoA,
YAP, and TAZ were localized in murine (ID8, 28-2) and
human (iOvCa130, iOvCa147) ovarian cancer cells that
either remained untreated, or were treated with 20 μM
simvastatin for 24 hr. Cells were fixed and permeabilized
as above and then incubated with SREBP-2 (Abcam
ab28482 1:200 dilution), RhoA (Abcam ab32046; 1:400
dilution), YAP (Santa Cruz sc-101199; 1:100 dilution),
or TAZ (Santa Cruz sc-48805; 1:200 dilution) antibodies
overnight at 4°C. Fluorescence-conjugated secondary
antibodies (Invitrogen, 1:100 dilution) were then added
for 2 hrs at room temperature, and cells were mounted
as above. Images were captured with an Olympus epifluorescence microscope and integrated morphometry
software (MetaMorph; Burlingame, CA).

Scratch assay
ID8 cells were seeded in 6-well plates in 10% FBS
growth medium. After serum deprivation for 24 hrs, cells
were treated with sublethal doses (0.5, 1.0 and 3.0 μM)
of simvastatin. After 48 hrs, cells were wounded by
scratching the plates with 200 μl pipette tip, washed with
PBS and media containing simvastatin. Three areas were
marked along the scratch and photomicrographs were
collected at 4× magnification with an Olympus 1 × 71
inverted microscope. Additional micrographs were
collected at the indicated areas 48 hrs later and the area
migrated was measured using image J software. The
percent wound closure was calculated by dividing the
distance at time zero from the distance of the wound at the
final time point.

ChIP assay
ChIP was performed using a modification of
previously published methods [80, 81]. ID8 and 28-2
cells at 70–80% confluency (3 – 1 × 107 cells/per cell line)
were washed once with PBS and incubated with 1%
formaldehyde (in control medium) for 10 min at room
temperature to cross-link proteins and DNA. Precleared
chromatin was aliquoted into 300 µl amounts and
incubated with 4 μg antibodies against acetylated
histone H3 [K9,14] (Cat #05-399 from Millipore) at
4°C overnight. Two aliquots were reserved as controls
– one incubated without antibody and the other with
non-immune IgG. Protein A/G Plus agarose beads (60
µl) were added to each tube, the mixtures incubated
for 2 h at 4°C and the immune complexes collected by
centrifugation. Real-time PCR was employed using
forward (5′-AAGTTCAGAGAGGCCATGAAGGGA-3)
and reverse (5′-TCTGCAGTTATTAACCCAGCCGGT-3′)
primers that amplify a ~100 bp region surrounding the
proximal NF-Y response element, of the mouse HMGR
promoter [24]. This region is conserved between human,
mouse, and rat in the HMGR promoter [24]. Using serial
dilutions of human chromosomal DNA, these primers
were demonstrated to have equal efficiency in priming
their target sequences.

TUNEL assay
MOSEC lines were cultured on glass coverslips
in 24-well plates for 48 hrs before serum starvation
overnight, which was followed by 0.1, 1.0, 10.0 and 50 μM
simvastatin treatment. A second treatment at 48 hrs was
followed by 10% formalin fixation at 60 hrs and storage
in PBS at 4°C. To fluorescently label apoptotic cells,
the terminal uridine nucleotide end-labeling (TUNEL)
reaction was performed on sections to identify DNA
strands breaks, a hallmark of apoptosis using the in situ
cell death detection kit (Roche). Briefly, cells were
permeabilized with Triton X-100, incubated with TUNEL
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DNA sequencing

fading reagent was applied to the slides and imaging
was done using the SkyView system (Applied Spectral
Imaging). The total nuclear DNA content was measured by
a BD FacsScan flow cytometer using a standard protocol
including ethanol fixed, RNase treated and propidium
iodide stained cells from ID8, 28-2 and a normal fibroblast
control. The data was analyzed by an univariate cell cycle
model and the mean G1 peak values were compared
among cell cultures in FlowJo V10.1.

RNA was extracted from ID8 and 28-2 cell lines
with RNeasy plus mini kit (Qiagen #74134) After
PBS wash, 1 × 106 cells were collected in the lysis
buffer and following the manufacturer’s instructions.
cDNA synthesis was performed using 1 ug RNA with
Quanta qScript cDNA supermix (Quanta #95048100), according the manufacturer’s protocol. Primers
were designed with Geneious Pro 3.8.5 software
on mouse Trp53 cDNA (GenBank cDNA isoform a
gi|187960038|ref|NM_011640.3|). One of the primer pairs
annealed to exon-exon junctions to avoid amplification of
genomic DNA. Primer sequences were as follows:
mp53cdna-F1: GCTCACCCTGGCTAAAGTTC;
mp53cdna-F2: CAAGTCTGTTATGTGCACGTACTCTC;
mp53cdna-F3: AGGGAGCGCAAAGAGAGC;
mp53cdna-R1: TGAGGGGAGGAGAGTACGTG;
mp53cdna-R2: GTGGGCAGCGCTCTCTTT; mp53c
dna-R3: AAAAGAGGGAGACAGGGTGG. Oligos were
ordered from Laboratory Services Division University
of Guelph. PCR products were amplified using 1 ul
cDNA in 20 ul reactions contain 10 ul AmpliTaqGold
360 master mix (Applied Biosystem #439881) and 2
ul 5 pM forward-reverse primer mix. PCR products
were confirmed with electrophoresis on 1% Agarose
gel. PCR samples were sent for purification and Sanger
sequencing to the Genomics Facility, University of
Guelph. Sequencing data was analyzed and assembled
to the mouse Trp53 gene cDNA reference ( GenBank
cDNA isoform a gi|187960038|ref|NM_011640.3|) with
Geneious Pro 3.8.5 software.

Immunoblot and cell fractionation
Cells and tumors were lysed and subjected to
Western blot analysis as we have done previously [82, 83].
Membranes were probed overnight at 4°C for total p53
(Abcam ab26; 1:500 dilution), mutant p53 (Abcam
ab32049; 1:500 dilution), Yap (Santa Cruz sc-101199;
1:500 dilution), Taz (Santa Cruz sc-48805; 1:500
dilution), HMGCR, (Santa Cruz sc-271595; 1:1000
dilution), Rac1 (Santa Cruz sc-95; 1:200 dilution), or
RhoA (Abcam ab32046; 1:500 dilution). Membranes
were then incubated with anti-rabbit or anti–mouse
secondary antibodies (Sigma; 1:5000 dilution). Western
Lightning Chemiluminescence Reagent Plus (PerkinElmer
BioSignal, Inc., Montreal, QC). Computer assisted
densitometry was performed using AlphaEase FC
software (AlphaInnotech, San Leandro, CA) and results
were quantified and reported as integrated densitometry
values (IDV) relative to β-actin or GAPDH. For cell
fractionation, cell cytoplasmic and nuclear fractions were
separated according to the REAP protocol [84]. Briefly,
ID8 or 28-2 cells were cultured in SF media, or were
treated with simvastatin (20 μM) for 24 hr and scraped
in ice-cold PBS. Cells were triturated in 0.1% Igepal
(ca-630; Sigma) in PBS and centrifuged. The supernatant
represented the cytoplasmic fraction. The remaining
pellet was resuspended in 0.1% Igepal and re-centrifuged
to generate the nuclear fraction. Samples were boiled in
sample buffer and prepared for SDS PAGE and analyzed
by Western blot analysis as above.

Chromosome analysis by flow cytometry and
spectral karyotyping
For spectral karyotyping, metaphase chromosome
spreads were prepared from ID8 and 28-2 cell cultures
grown in DMEM/10% FBS/1% ABAM/2% L-Glutamine
medium by adding 0.04 μg/ml KaryoMax Colcemid
for 1hr and followed by trypsin, hypotonic and MeOH/
AcOH 3:1 fixative treatments according to standard
cytogenetic procedures. Slides were aged overnight
at 37°C in a dry oven prior to spectral karyotyping,
according to manufacturer’s recommendations (Applied
Spectral Imaging). Briefly, slides were treated with pepsin,
dehydrated in ethanol series, denatured at 72°C for 1 min,
then quenched in ice-cold ethanol series. Probe mixtures
were denatured at 80°C for 7 min and pre-annealed at
37°C then applied to the slides and hybridized at 37°C
overnight. Washes were performed in 0.4% SSC at
72°C for 5 min and in 4 × SSC/0.1% Tween 20 at room
temperature, followed by sequential blocking steps of
incubation at 37°C for 30 min, thendetection reagents
at 37°C for 45 min and triple washes in 4 × SSC/0.1%
Tween 20 at 45°C for 2 min each. Finally DAPI/antiwww.impactjournals.com/oncotarget

Animal trials
C57Bl6 mice were purchased at Charles Rivers Labs
and housed at the Central Animal Facility, University of
Guelph, under the guidelines for Canadian Council for
Animal Care. ID8 cells were injected into the ovarian
bursa of recipient mice as described before [33]. Briefly,
mice were anesthetised with isofluorane, a small midline
dorsal incision was made and ID8 cells (1.0 × 106 cells in
5 μl of PBS) were injected into the left ovarian bursa with
a Hamilton syringe. After incision closure with staples,
the mice were monitored as they recovered for the next
24 hrs. To determine the effects of simvastatin treatment
on ovarian cancer progression, mice received daily
intraperitoneal injection of 1 mg/kg/day simvastatin or
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PBS as vehicle control one week after the bursal injection
of the ID8 cells (n = 6 mice/group). At 60 d post tumor
induction, mice were euthanized by CO2 asphyxiation and
ovarian weight was quantified. To determine the effect of
simvastatin treatment on advanced-stage disease, tumors
were induced as above and were allowed to grow without
intervention for 60 d, at which time mice exhibited large
primary tumors, numerous metastatic abdominal tumors,
and abdominal ascites. Mice were then treated with daily
intraperitoneal injections of 1 mg/kg/day simvastatin
or PBS for 20 d until 80 d post-tumor induction (PTI)
(n = 6 mice/group). At 80 d PTI, mice were euthanized
and tumors removed and weighed, the number of
metastatic abdominal tumors were counted to generate a
scoring system (0 peritoneal tumors – 0; 1–3 peritoneal
tumors − +; 4–10 peritoneal tumors − ++, and 11 or more
peritoneal tumors − +++) and ascites-derived cell viability
was assessed using a Trypan Blue exclusion test. Some
of the metastatic abdominal tumors were also removed
for histological analysis of members of the mevalonate
pathway. To compare expression and localization of
members of the mevalonate pathway, a portion of primary
ovarian, and metastatic abdominal tumors were fixed
overnight in 10% neutral buffered formalin, processed,
and embedded in paraffin wax and cut into 5 μM sections
on glass coverslips. Paraffin-embedded sections were
deparafinized, rehydrated and endogenous peroxidases
were blocked by incubation with 1% hydrogen peroxide
for 10 min at room temperature (RT). Antigen retrieval
was conducted by immersing sections in 10 mM citrate
buffer at 90°C for 12 minutes. Tissues were blocked for
10 min at RT with 5% normal serum and incubated with
anti-HMGCR (Santa Cruz sc-271595; 1:200 dilution),
Rac1 (Santa Cruz sc-95 ; 1:400 dilution), or RhoA
(Abcam ab32046; 1:400 dilution) overnight at 4°C in a
humidity chamber. Slides were incubated with biotinylated
secondary antibody (Sigma-Aldrich Canada Ltd.,
Oakville, ON) for 2 hours at RT followed by ExtrAvidin
(Sigma-Aldrich; 1:100 dilution) for 1 hour at RT. The
primary antibodies were visualized using DAB (SigmaAldrich Canada Ltd., Oakville, ON) and counterstained
with Carazzi’s Hematoxylin. After slides were dehydrated
and mounted on coverslips they were imaged using
brightfield microscopy. Another portion of the primary
and metastatic secondary tumors was lysed in RIPA buffer
and subjected to Western blot analysis as described above.
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